Jinling Pharmaceutical Co., Ltd. (000919) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Jinling Pharmaceutical Co., Ltd.

Why is Jinling Pharmaceutical Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of 7.38% and Operating profit at -189.29% over the last 5 years

The company has declared positive results in Jan 70 after 4 consecutive negative quarters

OPERATING CASH FLOW(Y) Highest at CNY 289.57 MM
NET PROFIT(Q) At CNY 21.68 MM has Grown at 348.31%
RAW MATERIAL COST(Y) Fallen by -30.83% (YoY)

With ROE of -0.18%, it has a fair valuation with a 1.13 Price to Book Value

Over the past year, while the stock has generated a return of 2.04%, its profits have fallen by -107.5%
At the current price, the company has a high dividend yield of 1.2

Underperformed the market in the last 1 year

The stock has generated a return of 2.04% in the last 1 year, much lower than market (China Shanghai Composite) returns of 15.17%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Jinling Pharmaceutical Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Jinling Pharmaceutical Co., Ltd. for you?

Medium Risk, Low Return

Absolute

Risk Adjusted

Volatility

Jinling Pharmaceutical Co., Ltd.

-100.0%

0.28

25.30%

China Shanghai Composite

15.45%

1.02

14.86%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

7.38%

EBIT Growth (5y)

-189.29%

EBIT to Interest (avg)

72.37

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.35

Sales to Capital Employed (avg)

0.82

Tax Ratio

100.00%

Dividend Payout Ratio

146.63%

Pledged Shares

Institutional Holding

ROCE (avg)

4.77%

ROE (avg)

3.84%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.13

EV to EBIT

-16.91

EV to EBITDA

24.23

EV to Capital Employed

1.38

EV to Sales

0.54

PEG Ratio

Dividend Yield

1.18%

ROCE (Latest)

-8.15%

ROE (Latest)

-0.18%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

20What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CNY 289.57 MM

NET PROFIT(Q)

At CNY 21.68 MM has Grown at 348.31%

RAW MATERIAL COST(Y)

Fallen by -30.83% (YoY

CASH AND EQV(HY)

Highest at CNY 5,224.14 MM

DEBT-EQUITY RATIO (HY)

Lowest at -61.41 %

DEBTORS TURNOVER RATIO(HY)

Highest at 4.72 times

PRE-TAX PROFIT(Q)

Highest at CNY 30 MM

-10What is not working for the Company

INTEREST(HY)

At CNY 2.92 MM has Grown at 665.46%

NET SALES(Q)

Lowest at CNY 779.07 MM

Here's what is working for Jinling Pharmaceutical Co., Ltd.

Pre-Tax Profit

At CNY 30 MM has Grown at 756.86%

over average net sales of the previous four periods of CNY -4.57 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CNY MM)

Net Profit

At CNY 21.68 MM has Grown at 348.31%

over average net sales of the previous four periods of CNY 4.84 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (CNY MM)

Operating Cash Flow

Highest at CNY 289.57 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Pre-Tax Profit

Highest at CNY 30 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Cash and Eqv

Highest at CNY 5,224.14 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at -61.41 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Debtors Turnover Ratio

Highest at 4.72 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -30.83% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Jinling Pharmaceutical Co., Ltd.

Interest

At CNY 2.92 MM has Grown at 665.46%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Net Sales

Lowest at CNY 779.07 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Net Sales

At CNY 779.07 MM has Fallen at -10.41%

over average net sales of the previous four periods of CNY 869.58 MM

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)